VivoSim Enters China Market With Initial Preclinical Testing Contracts
MT Newswires Live
Jul 21
VivoSim (VIVS) said Tuesday it won its first commercial agreements in mainland China to provide preclinical safety and drug efficacy testing services.
The initial contracts with an oncology biotechnology company in Shanghai and a pharmaceutical business in Chengdu involve gastrointestinal toxicology screening and efficacy profiling for candidate molecules, the company said.
The company obtained both customer orders through its regional distributor Tekon, VivoSim said.
Shares of the company were up 17% in Tuesday premarket trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.